{
  "abstract": "Recent advances in neurodegenerative biomarker research shed light on beta-synuclein as a promising indicator of synaptic dysfunction in Alzheimer’s disease (AD) and related dementias. Two noteworthy studies—Barba et al 1 and Kong and Jung2—independently demonstrate that serum beta-synuclein levels are significantly associated with clinical staging and synaptic degeneration. Barba et al 1 showed that beta-synuclein levels progressively increase across the AD continuum, from preclinical to mild cognitive impairment and dementia, supporting its role as a marker of disease severity. This cross-sectional pattern provides a foundation for understanding beta-synuclein’s potential as a staging biomarker.",
  "authors": [
    {
      "affiliations": [
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden",
        "Turku PET Centre, Turku University Central Hospital, Turku, Southwest Finland, Finland"
      ],
      "name": "Marco Bucci"
    }
  ],
  "title": "Beta-synuclein: a dynamic biomarker and modulator in neurodegenerative dementia",
  "uid": "b1786496-7fa5-5a17-87d8-80ff4ab4430d"
}